Navigation Links
Boston Scientific Second Quarter Results Exceed Consensus Sales and EPS; Full-Year Guidance Raised
Date:7/28/2011

NATICK, Mass., July 28, 2011 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) today announces financial results for the second quarter ended June 30, 2011, as well as net sales and earnings per share (EPS) guidance for the third quarter and updated guidance for the full year 2011.  The Company exceeded its EPS guidance range for the quarter and is raising EPS guidance for the remainder of the year.

Delivering strong execution of its POWER business strategy, the Company also announces the prepayment of the remaining $750 million of its term loan borrowings, which reduced its gross debt to $4.2 billion, consistent with the target capital structure, with no further debt maturities until 2014; a new $1.0 billion share repurchase program; and a productivity-enhancing restructuring program as anticipated during the Company’s Investor Day held in November 2010.  Yesterday, the Company announced an additional $150 million investment in China to drive growth and increase market share through local manufacturing, physician training and an expanded commercial footprint.  

Second quarter and other highlights:

  • Achieved second quarter sales of $1.975 billion, at the higher end of the Company's previous guidance range, and reported GAAP earnings of $0.10 per share, a 66 percent increase over the second quarter of 2010, and adjusted EPS of $0.17, a 42 percent increase over the second quarter of 2010, both exceeding previous guidance

  • Received FDA approval and launched in the U.S. the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System, the Company’s third-generation drug-eluting stent (DES) technology, driving its U.S. DES market share to 50 percent and maintaining its worldwide DES market leadership at 36 percent

  • Launched the Company’s next-generation ENERGEN™ and PUNCTUAT
    '/>"/>

  • SOURCE Boston Scientific Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

    Related medicine technology :

    1. Boston Scientific Announces Five-Year, $150 Million Investment in China to Accelerate Commercial Expansion
    2. Boston Scientific to Webcast Conference Call Discussing Second Quarter 2011 Financial Results
    3. Boston Scientific Completes Clinical Trial Enrollment for Adapt™ Monorail™ Carotid Stent System
    4. Boston Scientific Announces U.S. and European Launch of Interlock™ - 35 Fibered IDC™ Occlusion System
    5. Boston Scientific Welcomes Passage of Patent Reform Bill
    6. Boston Scientific to Donate $1 Million to ASGEs IT & T Capital Campaign to Build a New State-of-the-Art GI Training Center
    7. Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter
    8. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents
    9. Boston Scientific Announces Voluntary Recall of iCross™ Coronary Imaging Catheters
    10. Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System
    11. Boston Heart Lab Changes Name to Boston Heart Diagnostics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
    (Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
    (Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
    Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
    ... ANA598 demonstrates favorable preclinical antiviral, metabolic, ... preliminary toxicologic properties, SAN DIEGO, Sept. 11 ... preclinical data today on ANA598, a,non-nucleoside inhibitor of ... the 14th International Symposium on Hepatitis C Virus ...
    ... have or have,ever had chronic heartburn, you may be ... severe gastroesophageal reflux disease,(GERD). Barrett,s esophagus has been recognized ... esophagus, the seventh deadliest cancer in men in,the United ... in the lining of the,esophagus, which can progress to ...
    Cached Medicine Technology:Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4It's Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer 2
    (Date:4/24/2014)... of Manchester have identified a way to sensitise cancer ... treatment. , The study published today in Cell ... of drugs to target cells that have become resistant ... whilst exploring the possible mechanisms behind resistance to chemotherapy ... colon cancer. , Dr Andrew Gilmore, who led the ...
    (Date:4/24/2014)... 2014 Scientific research at UT Southwestern Medical Center ... itself completely, whereas the adult heart lacks this ability. ... why the heart loses its incredible regenerative capability in ... , Yes, oxygen. It is well-known that a ... blood throughout the body. But at the same time, ...
    (Date:4/24/2014)... coated with an antimicrobial peptide could help to lower the ... Optometry and Vision Science , official journal of ... is published by Lippincott Williams & Wilkins , a ... animals and now humans support the biocompatibility and safety of ... new research by Debarun Dutta, B.Optom, of The University of ...
    (Date:4/24/2014)... DURHAM, N.C. Changes in managing patients before, during ... days and reduced readmission rates, according to researchers who ... Hospital. , The practice, called enhanced recovery, is easier ... period and bowel evacuation that are typically prescribed. After ... as soon as possible, leading to faster recoveries. , ...
    (Date:4/24/2014)... the new Institute for Biomedical Sciences at Georgia ... federal grant to develop novel therapeutics against Respiratory ... the Eunice Kennedy Shriver National Institute Of Child ... of Health will support Plemper,s drug development goals ... one distinct alternative compound. , Infections by RSV, ...
    Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Oxygen diminishes the heart's ability to regenerate, researchers discover 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3
    ... thousands of elderly people in England have come under ... for Social Care Inspection many elderly people found their ... trust. ,The practice of giving 15 minute ... individual, was accused fo being "undignified and unsafe". The ...
    ... An HIV/AIDS vaccine has proved to be efficient on animals according ... ,"Perhaps we can cure HIV infection. This is our hope," said ... of the vaccine are expected soon with almost $5i million to ... this new medical revelation. ,Dr. Yong Kang said, ...
    ... have conducted a randomised, placebo controlled, double blind trial on ... the popular antiaging// supplement DHEA(dehydroepiandrosterone). The report published in the ... with the findings that DHEA cannot be considered the magic ... that the drug does not have any marked impact on ...
    ... effects of the country's worst epidemic of the mosquito-borne ... been infected by Chikungunya,// according to the World Health ... by the WHO, over 1.25 million suspected cases have ... is debilitating with severe joint pain and high fever. ...
    ... A new experimental vaccine developed by scientists in the US ... help prevent the disease that has kills one million// people ... S and developed by Walter Reed Army Institute of Research ... percent for up to 18 months after vaccination among children ...
    ... Hopkins have shown that transplanting human stem cells into ... disease delays the start of nerve// cell damage typical ... stem cells develop into nerve cells that make substantial ... to Lou Gehrig’s, also known as amyotrophic lateral sclerosis ...
    Cached Medicine News:Health News:Standards of Home Care for Elderly Needs Change 2Health News:The Search For Eternal Youth-DHEA Not The Magic Potion 2Health News:45% of Indians Affected by Chikungunya Fever 2Health News:Human Stem Cells Delay Start of Lou Gehrig’s Disease in Rat 2Health News:Human Stem Cells Delay Start of Lou Gehrig’s Disease in Rat 3
    The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
    ... The Sysmex CA-7000 provides speed ... that is synonymous with Sysmex technology. ... CA-7000 offers throughput of up to ... hour in multi-parameter testing. This ...
    ... The Sysmex CA-1500 enhances productivity in the ... utilizes three detection methods clotting, chromogenic ... accurate and precise test results every time. ... communication options and random access, the CA-1500 ...
    ... is the lancing device that has set ... since 1983. This re-usable lancing device assists ... The auto-Lancet is constructed in the USA ... after day, year after year. It's the ...
    Medicine Products: